Ad-hoc RELEASE Announcement according to Article 17 European Market Abuse Regulation (MAR) Biotest AG: Delisting agreement and announced delisting tender offer eieich, March 31, 2025: Biotest AG (ISIN DE0005227201, ISIN DE0005227235) has today concluded a delisting agreement with its major shareholder, Grifols, S.A., which holds approximate [ … ]

    PRESS RELEASE   Biotest AG increases sales by 6% in financial year 2024 EBIT guidance of € 94.5 million at the upper end of the forecast range achieved Marketing authorization application for fibrinogen submitted in key European markets and to the US Food and Drug Administration (FDA) Approval of Yimmugo in June 2024 by the US Food and D [ … ]

Ad hoc NOTICE Notification pursuant to Art. 17 EU Market Abuse Regulation (MAR)   CFO Martin Möller to leave Biotest as planned at the end of his contract. Position of CFO to be filled in the near future Dreieich, Germany, 6 March 2025. The Board of Management of Biotest AG announces that Chief Financial Officer Martin Möller will terminate his [ … ]

  Ad-hoc RELEASE Announcement according to Article 17 European Market Abuse Regulation (MAR)  Biotest publishes preliminary business figures - 2024 forecasts partially exceeded Dreieich, 26 February 2025: According to preliminary and unaudited figures, the Biotest Group generated revenue of € 726.2 million in the 2024 financial year, compared [ … ]

PRESS RELEASE   Important milestone for Biotest: Biologics License Application for Fibrinogen submitted to the US Food and Drug Administration (FDA)   Biotest's fibrinogen aims to fulfill a high unmet medical need for additional fibrinogen to treat acquired fibrinogen deficiency US submission follows EU application for marketing authorizatio [ … ]